Skip to content
← All treatment topics

TREATMENT READING

Pancreatic Cancer

Source sections for this topic, with the original link and date. Patient and professional reading are labelled separately.

Not medical advice · Not a complete treatment or trial directory

Made by Triangle.

Selected text from the National Cancer Institute, with the original link and date. Made by Triangle. This page is not an NCI PDQ summary. Source topics may be broader than an individual diagnosis.

46 sections
  1. Palliative Therapy
  2. Treatment Option Overview for Pancreatic Cancer
  3. Capecitabine and Fluorouracil Dosing
  4. Treatment of Resectable or Borderline Resectable Pancreatic Cancer
  5. Treatment Options for Resectable or Borderline Resectable Pancreatic Cancer
  6. Neoadjuvant therapy
  7. Surgery
  8. Postoperative chemotherapy
  9. Postoperative chemoradiation therapy
  10. Treatment of Locally Advanced Pancreatic Cancer
  11. Treatment Options for Locally Advanced Pancreatic Cancer
  12. Chemotherapy with or without targeted therapy
  13. Chemoradiation therapy
  14. Surgery
  15. Palliative surgery
  16. Treatment of Metastatic or Recurrent Pancreatic Cancer
  17. Treatment Options for Metastatic or Recurrent Pancreatic Cancer
  18. Chemotherapy with or without targeted therapy
  19. Special considerations for patients with germline BRCA1/BRCA2 variants
  20. Olaparib
  21. Palliative Therapy
  22. Certain factors affect prognosis (chance of recovery) and treatment options.
  23. The following groups are used to plan treatment:
  24. Resectable pancreatic cancer
  25. Borderline resectable pancreatic cancer
  26. Locally advanced pancreatic cancer
  27. Metastatic pancreatic cancer
  28. Recurrent pancreatic cancer
  29. Treatment Option Overview
  30. Key Points
  31. There are different types of treatment for patients with pancreatic cancer.
  32. The following types of treatment are used:
  33. Surgery
  34. Radiation therapy
  35. Chemotherapy
  36. Chemoradiation therapy
  37. Targeted therapy
  38. There are treatments for pain caused by pancreatic cancer.
  39. Patients with pancreatic cancer have special nutritional needs.
  40. New types of treatment are being tested in clinical trials.
  41. Treatment for pancreatic cancer may cause side effects.
  42. Follow-up care may be needed.
  43. Treatment of Resectable or Borderline Resectable Pancreatic Cancer
  44. Treatment of Locally Advanced Pancreatic Cancer
  45. Treatment of Metastatic or Recurrent Pancreatic Cancer
  46. Palliative Therapy

Health professional · General Information About Pancreatic Cancer

Palliative Therapy

Source: Pancreatic Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: February 12, 2025. Captured 2026-09-09.

Palliation of symptoms may be achieved with conventional treatment (systemic chemotherapy).

Palliative measures that may improve quality of life without affecting OS include:[11,12]

Sources: 11 · 12

Surgical or radiological biliary decompression.

Relief of gastric outlet obstruction.

Pain control.

Psychological care to address the potentially disabling psychological events associated with the diagnosis and treatment of pancreatic cancer.[13]

Sources: 13

This page is made by Triangle. The reading above is selected source text, not a treatment recommendation, and it is not medical advice.

Health professional

Treatment Option Overview for Pancreatic Cancer

Source: Pancreatic Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: February 12, 2025. Captured 2026-09-09.

Surgical resection, when feasible, remains the primary treatment modality for patients with pancreatic cancer. On occasion, resection can lead to long-term survival, and it provides effective palliation.[1-3][Level of evidence C1] Treatment is often guided by resectability, but this may vary depending on surgical judgment and experience. Referral to a high-volume center should be considered.[4]

Sources: 1 · 3 · Level of evidence C1 · 4

Postoperative chemotherapy improves overall survival, but the role of chemoradiation remains controversial.

Complications of pancreatic cancer include:

Malabsorption: Frequently, malabsorption caused by exocrine insufficiency contributes to malnutrition. Pancreatic enzyme replacement can help alleviate this problem.

Pain: Celiac axis and intrapleural nerve blocks can provide highly effective and long-lasting control of pain for some patients. For more information, see Cancer Pain.

Sources: Cancer Pain

The survival rate of patients with any stage of pancreatic exocrine cancer is poor. Clinical trials are appropriate for patients with any stage of disease and should be considered before palliative approaches are selected.

Information about ongoing clinical trials for pancreatic cancer is available from the NCI website.

Sources: NCI website

Table 6. Treatment Options for Pancreatic Cancer
Clinical StageTreatment Options
Resectable or borderline resectable pancreatic cancerNeoadjuvant therapy
Surgery
Postoperative chemotherapy
Postoperative chemoradiation therapy
Preoperative chemotherapy and/or radiation therapy (under clinical evaluation)
Alternative radiation techniques (under clinical evaluation)
Locally advanced pancreatic cancerChemotherapy with or without targeted therapy
Chemoradiation therapy
Surgery
Palliative surgery
Clinical trials evaluating novel agents in combination with chemotherapy or chemoradiation therapy for patients with unresectable tumors
Intraoperative radiation therapy and/or implantation of radioactive sources (under clinical evaluation)
Metastatic or recurrent pancreatic cancerChemotherapy with or without targeted therapy
Clinical trials evaluating new anticancer agents alone or in combination with chemotherapy

Sources: Clinical Stage · Neoadjuvant therapy · Surgery · Postoperative chemotherapy · Postoperative chemoradiation therapy · Chemotherapy with or without targeted therapy · Chemoradiation therapy · Surgery · Palliative surgery · Chemotherapy with or without targeted therapy

Palliative therapies can be considered in patients with any stage of disease. For more information, see the Palliative Therapy section.

Sources: Palliative Therapy

Health professional · Treatment Option Overview for Pancreatic Cancer

Capecitabine and Fluorouracil Dosing

Source: Pancreatic Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: February 12, 2025. Captured 2026-09-09.

The DPYD gene encodes an enzyme that catabolizes pyrimidines and fluoropyrimidines, like capecitabine and fluorouracil. An estimated 1% to 2% of the population has germline pathogenic variants in DPYD, which lead to reduced DPD protein function and an accumulation of pyrimidines and fluoropyrimidines in the body.[5,6] Patients with the DPYD*2A variant who receive fluoropyrimidines may experience severe, life-threatening toxicities that are sometimes fatal. Many other DPYD variants have been identified, with a range of clinical effects.[5-7] Fluoropyrimidine avoidance or a dose reduction of 50% may be recommended based on the patient's DPYD genotype and number of functioning DPYD alleles.[8-10] DPYD genetic testing costs less than $200, but insurance coverage varies due to a lack of national guidelines.[11] In addition, testing may delay therapy by 2 weeks, which would not be advisable in urgent situations. This controversial issue requires further evaluation.[12]

Sources: 5 · 6 · 5 · 7 · 8 · 10 · 11 · 12

Health professional

Treatment of Resectable or Borderline Resectable Pancreatic Cancer

Source: Pancreatic Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: February 12, 2025. Captured 2026-09-09.

Health professional · Treatment of Resectable or Borderline Resectable Pancreatic Cancer

Treatment Options for Resectable or Borderline Resectable Pancreatic Cancer

Source: Pancreatic Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: February 12, 2025. Captured 2026-09-09.

Treatment options for resectable or borderline resectable pancreatic cancer include:

Neoadjuvant therapy: Neoadjuvant chemotherapy with or without chemoradiation therapy.

Sources: Neoadjuvant therapy

Surgery: Radical pancreatic resection including:

Sources: Surgery

Surgery: Radical pancreatic resection including:

Whipple procedure (pancreaticoduodenal resection).

Total pancreatectomy when necessary for adequate margins.

Distal pancreatectomy for tumors of the body and tail of the pancreas.[1,2]

Sources: 1 · 2

Postoperative chemotherapy: Radical pancreatic resection followed by chemotherapy.[3]

Sources: Postoperative chemotherapy · 3

Postoperative chemoradiation therapy: Radical pancreatic resection followed by fluorouracil (5-FU) chemotherapy and radiation therapy.[4-8]

Sources: Postoperative chemoradiation therapy · 4 · 8

Preoperative chemotherapy and/or radiation therapy (under clinical evaluation).

Alternative radiation techniques (under clinical evaluation).

Palliative therapies can be considered in patients with any stage of disease. For more information, see the Palliative Therapy section.

Sources: Palliative Therapy

Health professional · Treatment of Resectable or Borderline Resectable Pancreatic Cancer / Treatment Options for Resectable or Borderline Resectable Pancreatic Cancer

Neoadjuvant therapy

Source: Pancreatic Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: February 12, 2025. Captured 2026-09-09.

Neoadjuvant therapy is chemotherapy with or without chemoradiation therapy given before surgery. The role of neoadjuvant therapy has been evaluated in retrospective studies (Surveillance, Epidemiology, and End Results [SEER] Program database and National Cancer Database) and is recommended by multiple consensus guidelines for the management of patients with borderline resectable pancreatic cancer. It is being evaluated in patients with resectable or borderline resectable pancreatic cancer in several ongoing trials.[9-11]

Sources: 9 · 11

Evidence (neoadjuvant chemotherapy with or without chemoradiation therapy):

The phase II, multicenter, randomized A021501 trial (NCT02839343) enrolled 126 patients with borderline resectable pancreatic cancer from institutions in the National Clinical Trials Network cooperative groups between 2017 and 2019. Patients were assigned to receive either eight 2-week cycles of modified FOLFIRINOX (oxaliplatin, leucovorin, irinotecan, and 5-FU) (n = 65) or seven 2-week cycles of modified FOLFIRINOX followed by stereotactic body radiotherapy (33 Gy–40 Gy in 5 fractions) or hypofractionated image-guided radiotherapy (25 Gy in 5 fractions) (n = 55). Patients without disease progression then underwent surgery followed by four 2-week cycles of adjuvant FOLFOX6 (oxaliplatin, leucovorin, and 5-FU).[12]

Sources: A021501 · 12

The phase II, multicenter, randomized A021501 trial (NCT02839343) enrolled 126 patients with borderline resectable pancreatic cancer from institutions in the National Clinical Trials Network cooperative groups between 2017 and 2019. Patients were assigned to receive either eight 2-week cycles of modified FOLFIRINOX (oxaliplatin, leucovorin, irinotecan, and 5-FU) (n = 65) or seven 2-week cycles of modified FOLFIRINOX followed by stereotactic body radiotherapy (33 Gy–40 Gy in 5 fractions) or hypofractionated image-guided radiotherapy (25 Gy in 5 fractions) (n = 55). Patients without disease progression then underwent surgery followed by four 2-week cycles of adjuvant FOLFOX6 (oxaliplatin, leucovorin, and 5-FU).[12]

In the neoadjuvant chemotherapy-alone arm, the median overall survival (OS) was 29.8 months (95% confidence interval [CI], 21.1–36.6) with a 43% microscopically margin-negative (R0) resection rate. This was compared with estimated historical controls of median OS at 18 months.[12][Level of evidence C3]

Sources: 12 · Level of evidence C3

Grade 3 or greater treatment-related adverse events occurred in 57% of patients who received neoadjuvant chemotherapy alone.

The neoadjuvant chemotherapy with radiation arm was closed at interim futility analysis because of low R0 resection rates (33%) in the first 30 patients enrolled.

The multicenter phase III PREOPANC trial included 246 patients diagnosed with resectable or borderline resectable pancreatic cancer between 2013 and 2017. Patients at 16 Dutch centers were randomly assigned to receive either diagnostic laparoscopy, neoadjuvant chemoradiation therapy, surgical resection, and four cycles of adjuvant gemcitabine or up-front surgery and six cycles of adjuvant gemcitabine. Neoadjuvant chemoradiation therapy included the following: cycle 1 (21 days) with gemcitabine 1,000 mg/m2 on days 1 and 8; cycle 2 (28 days) with gemcitabine on days 1, 8, and 15 with 15 concurrent fractions of hypofractionated radiation (36 Gy) to the tumor and suspected associated lymph nodes; and cycle 3 (21 days) with gemcitabine on days 1 and 8.[13] The optimal neoadjuvant therapy regimen is unknown, and additional chemotherapy regimens are being evaluated in the following trials: ALLIANCE (NCT04340141), PREOPANC-3 (NCT04927780), PANACHE-01-PRODIGE (NCT02959879), and NorPACT-01 (NCT02919787).

Sources: 13 · ALLIANCE · PREOPANC-3 · PANACHE-01-PRODIGE · NorPACT-01

The multicenter phase III PREOPANC trial included 246 patients diagnosed with resectable or borderline resectable pancreatic cancer between 2013 and 2017. Patients at 16 Dutch centers were randomly assigned to receive either diagnostic laparoscopy, neoadjuvant chemoradiation therapy, surgical resection, and four cycles of adjuvant gemcitabine or up-front surgery and six cycles of adjuvant gemcitabine. Neoadjuvant chemoradiation therapy included the following: cycle 1 (21 days) with gemcitabine 1,000 mg/m2 on days 1 and 8; cycle 2 (28 days) with gemcitabine on days 1, 8, and 15 with 15 concurrent fractions of hypofractionated radiation (36 Gy) to the tumor and suspected associated lymph nodes; and cycle 3 (21 days) with gemcitabine on days 1 and 8.[13] The optimal neoadjuvant therapy regimen is unknown, and additional chemotherapy regimens are being evaluated in the following trials: ALLIANCE (NCT04340141), PREOPANC-3 (NCT04927780), PANACHE-01-PRODIGE (NCT02959879), and NorPACT-01 (NCT02919787).

The 5-year OS rate was 20.5% (95% CI, 14.2%–29.8%) for patients who received neoadjuvant chemoradiation therapy and 6.5% (95% CI, 3.1%–13.7%) for patients who received up-front surgery (hazard ratio [HR], 0.73; 95% CI, 0.56–0.96; P = .025).[13][Level of evidence A1]

Sources: 13 · Level of evidence A1

The median OS was 15.7 months in the neoadjuvant chemoradiation therapy group and 14.3 months in the up-front surgery group.

In the intention-to-treat arm, 61% of patients who received neoadjuvant chemoradiation therapy underwent resection, resulting in R0 resection for 41% of patients and node-negative disease for 65% of patients. The resection rate was 72% in the up-front surgery arm, resulting in R0 resection in 28% of patients and node-negative disease in 18% of patients.

Health professional · Treatment of Resectable or Borderline Resectable Pancreatic Cancer / Treatment Options for Resectable or Borderline Resectable Pancreatic Cancer

Surgery

Source: Pancreatic Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: February 12, 2025. Captured 2026-09-09.

Complete resection can yield 5-year survival rates of 18% to 24%, but ultimate control remains poor because of the high incidence of both local and distant tumor recurrence. Thus, systemic therapy is also recommended.[14-16][Level of evidence C1]

Sources: 14 · 16 · Level of evidence C1

Approximately 20% of patients present with pancreatic cancer amenable to local surgical resection, with operative mortality rates of approximately 1% to 16%.[17-21] Using information from the Medicare claims database, a national cohort study of more than 7,000 patients undergoing pancreaticoduodenectomy between 1992 and 1995 revealed higher in-hospital mortality rates at low-volume hospitals (<1 pancreaticoduodenectomy per year) versus high-volume hospitals (>5 per year) (16% vs. 4%, respectively; P < .01).[17]

Sources: 17 · 21 · 17

Health professional · Treatment of Resectable or Borderline Resectable Pancreatic Cancer / Treatment Options for Resectable or Borderline Resectable Pancreatic Cancer

Postoperative chemotherapy

Source: Pancreatic Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: February 12, 2025. Captured 2026-09-09.

Historically, multiple randomized trials have established that adjuvant gemcitabine monotherapy [22] or adjuvant 5-FU monotherapy [3] improve OS for 6 months after surgical resection compared with surgery alone. More recent studies have looked at newer combination regimens that might further improve outcomes after surgical resection.

Sources: 22 · 3

For patients with good performance status, adjuvant FOLFIRINOX chemotherapy or the combination of gemcitabine and capecitabine should be considered. However, for older patients or patients with marginal performance status, adjuvant gemcitabine or 5-FU monotherapy can be considered. In Asia, S-1 (tegafur, gimeracil, and oteracil potassium) is an appropriate alternative to gemcitabine-based therapies.

Evidence (postoperative chemotherapy):

FOLFIRINOX: In the randomized, open-label, phase III PRODIGE-24 trial (NCT01526135), 493 patients with R0/R1 resections were randomly assigned 1:1 to receive six cycles of gemcitabine (1,000 mg/m2 on days 1, 8, and 15 of a 28-day cycle) or 12 cycles of FOLFIRINOX (oxaliplatin 85 mg/m2, leucovorin 400 mg/m2, irinotecan 150 mg/m2, and 5-FU 2,400 mg/m2 over 46 hours every 2 weeks).[23,24][Level of evidence A1]

Sources: PRODIGE-24 · 23 · 24 · Level of evidence A1

FOLFIRINOX: In the randomized, open-label, phase III PRODIGE-24 trial (NCT01526135), 493 patients with R0/R1 resections were randomly assigned 1:1 to receive six cycles of gemcitabine (1,000 mg/m2 on days 1, 8, and 15 of a 28-day cycle) or 12 cycles of FOLFIRINOX (oxaliplatin 85 mg/m2, leucovorin 400 mg/m2, irinotecan 150 mg/m2, and 5-FU 2,400 mg/m2 over 46 hours every 2 weeks).[23,24][Level of evidence A1]

With a median follow-up of 69.7 months, the median disease-free survival (DFS) was 21.4 months (95% CI, 17.5–26.7) in the FOLFIRINOX group and 12.8 months in the gemcitabine group (95% CI, 11.6–15.2) (HR, 0.66; 95% CI, 0.54–0.82; P < .001).

The median OS was 53.5 months (95% CI, 43.5–58.4) in the FOLFIRINOX group and 35.5 months (95% CI, 30.1–40.3) in the gemcitabine group (HR, 0.68; 95% CI, 0.54–0.85; P = .001). The 5-year OS rate was 43.2% in the FOLFIRINOX group and 31.4% in the gemcitabine group.

Toxicity was higher with combination therapy; 75.9% of patients who received FOLFIRINOX had grade 3 or 4 toxicities, compared with 52.9% of those who received gemcitabine, with similar rates of neutropenia (although 62.2% of patients on FOLFIRINOX received granulocyte colony-stimulating factor). Thirty-three percent of patients who received FOLFIRINOX stopped treatment prematurely, compared with 21% of patients who received gemcitabine alone.

Gemcitabine and capecitabine: The European Study for Pancreatic Cancer (ESPAC-4 [NCT00058201]) trial randomly assigned 732 patients with resected pancreatic cancer to receive either six cycles of gemcitabine alone (1,000 mg/m2 given weekly for 3 weeks of every 4 weeks) or oral capecitabine (1,660 mg/m2 given for 21 days followed by 7 days of rest [one cycle]).[25][Level of evidence A1]

Sources: ESPAC-4 · 25 · Level of evidence A1

Gemcitabine and capecitabine: The European Study for Pancreatic Cancer (ESPAC-4 [NCT00058201]) trial randomly assigned 732 patients with resected pancreatic cancer to receive either six cycles of gemcitabine alone (1,000 mg/m2 given weekly for 3 weeks of every 4 weeks) or oral capecitabine (1,660 mg/m2 given for 21 days followed by 7 days of rest [one cycle]).[25][Level of evidence A1]

With a median follow-up of 43.2 months, the median OS for patients in the gemcitabine/capecitabine group was 28.0 months (95% CI, 23.5–31.5) compared with 25.5 months for the gemcitabine-alone group (95% CI, 22.7–27.9; HR, 0.82; P = .032). Treatment with gemcitabine/capecitabine yielded an improvement in the estimated 5-year OS rate from 16.3% with gemcitabine alone to 28.8% with gemcitabine/capecitabine.

There was no significant difference in overall rates of grade 3/4 toxicities between treatment arms. Compared with gemcitabine alone, capecitabine was associated with higher rates of grade 3/4 diarrhea (5% vs. 2%), neutropenia (38% vs. 24%), and hand-foot syndrome (7% vs. 0%).

There was no significant effect on the quality of life in the treatment groups.

Based on these findings, the adjuvant combination of gemcitabine and capecitabine is the standard of care after a resection for pancreatic cancer.

S-1: The Japan Adjuvant Study Group of Pancreatic Cancer (JASPAC-01) study was a phase III, multicenter, noninferiority trial conducted in Japan that randomly assigned 385 patients to receive either gemcitabine (1,000 mg/m2 weekly for 3 weeks of every 4 weeks) for six cycles or S-1 (tegafur, gimeracil, and oteracil potassium) (given orally twice a day for 4 weeks followed by a 2-week break).[26][Level of evidence A1]

Sources: 26 · Level of evidence A1

S-1: The Japan Adjuvant Study Group of Pancreatic Cancer (JASPAC-01) study was a phase III, multicenter, noninferiority trial conducted in Japan that randomly assigned 385 patients to receive either gemcitabine (1,000 mg/m2 weekly for 3 weeks of every 4 weeks) for six cycles or S-1 (tegafur, gimeracil, and oteracil potassium) (given orally twice a day for 4 weeks followed by a 2-week break).[26][Level of evidence A1]

The prespecified criteria for early discontinuation was met at interim analysis for efficacy with all of the protocol treatments completed. On early interim analysis, the HRmortality was 0.57 (95% CI, 0.44–0.72; P for noninferiority < .001; P for superiority < .001). These results were associated with a 5-year OS rate of 24.4% in the gemcitabine group and 44.1% in the S-1 group.

Grade 3 or 4 leukopenia, neutropenia, and liver transaminitis were observed more frequently in the gemcitabine group, and stomatitis and diarrhea were experienced more frequently in the S-1 group.

Among Japanese patients, adjuvant chemotherapy with S-1 can be a new standard of care for resected pancreatic patients. Additional studies are needed to validate these results in patients of other races and ethnicities.

The pharmacokinetics and pharmacodynamics of S-1 may be different between Eastern and Western patient populations because grade 3/4 gastrointestinal toxicities, especially diarrhea, have been reported more commonly in the Western patient population. S-1 is not currently approved by the U.S. Food and Drug Administration for use in the United States.

Gemcitabine: Charité Onkologie (CONKO)-001 was a multicenter phase III trial of 368 patients with resected pancreatic cancer who were randomly assigned to receive six cycles of adjuvant gemcitabine versus observation.[22][Level of evidence B1] In contrast to the previous trials, the primary end point was DFS.

Sources: 22 · Level of evidence B1

Gemcitabine: Charité Onkologie (CONKO)-001 was a multicenter phase III trial of 368 patients with resected pancreatic cancer who were randomly assigned to receive six cycles of adjuvant gemcitabine versus observation.[22][Level of evidence B1] In contrast to the previous trials, the primary end point was DFS.

With a median follow-up of 136 months, long-term follow-up of the CONKO-001 study demonstrated a significant improvement in OS that favors gemcitabine (median survival, 22.8 months vs. 20.2 months; HR, 0.76; 95% CI, 0.61–0.95, P = .01). Gemcitabine compared with observation alone yielded improved survival rates at 5 years of 20.7% for the gemcitabine arm versus 10.4% for the observation-alone arm, and the survival rates at 10 years were 12.2% for the gemcitabine arm versus 7.7% for the observation-alone arm.[27][Level of evidence A1]

Sources: 27 · Level of evidence A1

Gemcitabine or 5-FU: The ESPAC-3 trial (NCT00058201) randomly assigned 1,088 patients who had undergone complete macroscopic resection to either 6 months of 5-FU (425 mg/m2) and leucovorin (20 mg/m2) on days 1 to 5 every 28 days or 6 months of gemcitabine (1,000 mg/m2) on days 1, 8, and 15 every 28 days.[3][Level of evidence A1]

Sources: ESPAC-3 · 3 · Level of evidence A1

Gemcitabine or 5-FU: The ESPAC-3 trial (NCT00058201) randomly assigned 1,088 patients who had undergone complete macroscopic resection to either 6 months of 5-FU (425 mg/m2) and leucovorin (20 mg/m2) on days 1 to 5 every 28 days or 6 months of gemcitabine (1,000 mg/m2) on days 1, 8, and 15 every 28 days.[3][Level of evidence A1]

Median OS was 23.0 months (95% CI, 21.1–25.0) for patients treated with 5-FU plus leucovorin and 23.6 months (95% CI, 21.4–26.4) for those treated with gemcitabine (HR, 0.94; 95% CI, 0.81–1.08; P = .39).

Health professional · Treatment of Resectable or Borderline Resectable Pancreatic Cancer / Treatment Options for Resectable or Borderline Resectable Pancreatic Cancer

Postoperative chemoradiation therapy

Source: Pancreatic Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: February 12, 2025. Captured 2026-09-09.

The role of postoperative therapy (chemotherapy with or without chemoradiation therapy) in the management of this disease remains controversial because much of the randomized clinical trial data available are statistically underpowered and provide conflicting results.[4-8]

Sources: 4 · 8

Evidence (postoperative chemoradiation therapy):

Several phase III trials examined the potential OS benefit of postoperative adjuvant 5-FU–based chemoradiation therapy:

Gastrointestinal Study Group (GITSG): A small randomized trial conducted by the GITSG in 1985 compared surgery alone with surgery followed by chemoradiation.[4][Level of evidence A1];[5][Level of evidence B4]

Sources: GITSG · 4 · Level of evidence A1 · 5 · Level of evidence B4

Gastrointestinal Study Group (GITSG): A small randomized trial conducted by the GITSG in 1985 compared surgery alone with surgery followed by chemoradiation.[4][Level of evidence A1];[5][Level of evidence B4]

The investigators reported a significant but modest improvement in median-term and long-term survival over resection alone with postoperative bolus 5-FU and regional split-course radiation given at a dose of 40 Gy.

European Organisation for the Research and Treatment of Cancer (EORTC): An attempt by the EORTC to reproduce the results of the GITSG trial failed to confirm a significant benefit for adjuvant chemoradiation therapy over resection alone;[6][Level of evidence A1] however, this trial treated patients with pancreatic and periampullary cancers (with a potentially better prognosis).

Sources: 6 · Level of evidence A1

European Organisation for the Research and Treatment of Cancer (EORTC): An attempt by the EORTC to reproduce the results of the GITSG trial failed to confirm a significant benefit for adjuvant chemoradiation therapy over resection alone;[6][Level of evidence A1] however, this trial treated patients with pancreatic and periampullary cancers (with a potentially better prognosis).

A subset analysis of the patients with primary pancreatic tumors indicated a trend toward improved median, 2-year, and 5-year OS with adjuvant therapy (17.1 months, 37%, and 20%, respectively) compared with surgery alone (12.6 months, 23%, and 10%, respectively); P = .09 for median survival).

An updated analysis of a subsequent ESPAC-1 trial examined only patients who underwent strict randomization after pancreatic resection. The patients were assigned to one of four groups (observation, bolus 5-FU chemotherapy, bolus 5-FU chemoradiation therapy, or chemoradiation therapy followed by additional chemotherapy).[7,8,28][Level of evidence A1]

Sources: 7 · 8 · 28 · Level of evidence A1

An updated analysis of a subsequent ESPAC-1 trial examined only patients who underwent strict randomization after pancreatic resection. The patients were assigned to one of four groups (observation, bolus 5-FU chemotherapy, bolus 5-FU chemoradiation therapy, or chemoradiation therapy followed by additional chemotherapy).[7,8,28][Level of evidence A1]

With a 2 × 2 factorial design reported at a median follow-up of 47 months, a median survival benefit was observed for only the patients who received postoperative 5-FU chemotherapy. However, these results were difficult to interpret because of a high rate of protocol nonadherence and the lack of a separate analysis for each of the four groups in the 2 × 2 design.

U.S. Gastrointestinal Intergroup: The U.S. Gastrointestinal Intergroup has reported the results of a randomized phase III trial (Radiation Therapy Oncology Group [RTOG]-9704) that included 451 patients with resected pancreatic cancers who were assigned to receive either postoperative infusional 5-FU plus infusional 5-FU and concurrent radiation or adjuvant gemcitabine plus infusional 5-FU and concurrent radiation.[29][Level of evidence A1] The primary end points were OS for all patients and OS for patients with pancreatic head tumors.

Sources: Radiation Therapy Oncology Group [RTOG]-9704 · 29 · Level of evidence A1

U.S. Gastrointestinal Intergroup: The U.S. Gastrointestinal Intergroup has reported the results of a randomized phase III trial (Radiation Therapy Oncology Group [RTOG]-9704) that included 451 patients with resected pancreatic cancers who were assigned to receive either postoperative infusional 5-FU plus infusional 5-FU and concurrent radiation or adjuvant gemcitabine plus infusional 5-FU and concurrent radiation.[29][Level of evidence A1] The primary end points were OS for all patients and OS for patients with pancreatic head tumors.

A 5-year update of RTOG-9704 reported that patients with pancreatic head tumors (n = 388) had a median survival of 20.5 months and a 5-year OS rate of 22% with gemcitabine, versus a median survival of 17.1 months and a 5-year OS rate of 18% with 5-FU (HR, 0.84; 95% CI, 0.67–1.05; P = .12).[30]

Sources: 30

Univariate analysis showed no difference in OS. However, on multivariate analysis, patients on the gemcitabine arm with pancreatic head tumors experienced a trend toward improved OS (P = .08). Distant relapse remained the predominant site of first failure (78%).

The EORTC/U.S. Gastrointestinal Intergroup RTOG-0848 phase III adjuvant trial evaluating the impact of chemoradiation therapy after completion of a full course of gemcitabine with or without erlotinib has closed and results are pending.

Sources: RTOG-0848

Additional trials are still warranted to determine more effective systemic therapy for this disease.

Health professional

Treatment of Locally Advanced Pancreatic Cancer

Source: Pancreatic Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: February 12, 2025. Captured 2026-09-09.

Health professional · Treatment of Locally Advanced Pancreatic Cancer

Treatment Options for Locally Advanced Pancreatic Cancer

Source: Pancreatic Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: February 12, 2025. Captured 2026-09-09.

While locally advanced and metastatic pancreatic cancer are both incurable, their natural histories may be different. An autopsy series demonstrated that 30% of patients presenting with locally advanced disease died without evidence of distant metastases.[1][Level of evidence A1] Therefore, investigators have struggled to determine whether chemoradiation therapy for patients presenting with locally advanced disease is warranted.

Sources: 1 · Level of evidence A1

Treatment options for locally advanced pancreatic cancer include:

Chemotherapy with or without targeted therapy.

Sources: Chemotherapy with or without targeted therapy

Chemoradiation therapy: Chemotherapy followed by chemoradiation for patients without metastatic disease.

Sources: Chemoradiation therapy

Surgery: Radical pancreatic resection.

Sources: Surgery

Palliative surgery: Palliative surgical biliary and/or gastric bypass, percutaneous radiologic biliary stent placement, or endoscopic biliary stent placement.[2,3]

Sources: Palliative surgery · 2 · 3

Clinical trials evaluating novel agents in combination with chemotherapy or chemoradiation therapy for patients with unresectable tumors.

Intraoperative radiation therapy and/or implantation of radioactive sources (under clinical evaluation).[4,5]

Sources: 4 · 5

Palliative therapies can be considered in patients with any stage of disease. For more information, see the Palliative Therapy section.

Sources: Palliative Therapy

Health professional · Treatment of Locally Advanced Pancreatic Cancer / Treatment Options for Locally Advanced Pancreatic Cancer

Chemotherapy with or without targeted therapy

Source: Pancreatic Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: February 12, 2025. Captured 2026-09-09.

Chemotherapy is the primary treatment modality for patients with locally advanced pancreatic cancers and uses the same regimens as those used to treat patients with metastatic disease.

Evidence (chemotherapy):

FOLFIRINOX versus gemcitabine: A multicenter phase II/III trial included 342 patients with metastatic pancreatic adenocarcinoma with an Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1.[6][Level of evidence A1] The patients were randomly assigned to receive FOLFIRINOX (oxaliplatin [85 mg/m2], irinotecan [180 mg/m2], leucovorin [400 mg/m2], and fluorouracil [5-FU; 400 mg/m2] given as a bolus followed by 2,400 mg/m2 given as a 46-hour continuous infusion, every 2 weeks) or gemcitabine (1,000 mg/m2 weekly for 7 of 8 weeks and then weekly for 3 of 4 weeks).

Sources: 6 · Level of evidence A1

FOLFIRINOX versus gemcitabine: A multicenter phase II/III trial included 342 patients with metastatic pancreatic adenocarcinoma with an Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1.[6][Level of evidence A1] The patients were randomly assigned to receive FOLFIRINOX (oxaliplatin [85 mg/m2], irinotecan [180 mg/m2], leucovorin [400 mg/m2], and fluorouracil [5-FU; 400 mg/m2] given as a bolus followed by 2,400 mg/m2 given as a 46-hour continuous infusion, every 2 weeks) or gemcitabine (1,000 mg/m2 weekly for 7 of 8 weeks and then weekly for 3 of 4 weeks).

The median overall survival (OS) was 11.1 months in the FOLFIRINOX group compared with 6.8 months in the gemcitabine group (hazard ratio [HR]death, 0.57; 95% confidence interval [CI], 0.45–0.73; P < .001).

Median progression-free survival (PFS) was 6.4 months in the FOLFIRINOX group and 3.3 months in the gemcitabine group (HRdisease progression, 0.47; 95% CI, 0.37–0.59; P < .001).

FOLFIRINOX was more toxic than gemcitabine; 5.4% of patients in this group had febrile neutropenia. At 6 months, 31% of the patients in the FOLFIRINOX group had a definitive degradation of quality of life, versus 66% in the gemcitabine group (HR, 0.47; 95% CI, 0.30–0.70; P < .001).

Based on this trial, FOLFIRINOX is considered a standard treatment option for patients with advanced pancreatic cancer.

Gemcitabine and nab-paclitaxel versus gemcitabine: A multicenter, international, phase III trial (NCT00844649) included 861 patients with metastatic pancreatic adenocarcinoma. Patients had a Karnofsky Performance Status of at least 70 and had not previously received chemotherapy for metastatic disease.[7][Level of evidence A1] Patients who received adjuvant gemcitabine or any other chemotherapy were excluded. The patients were randomly assigned to receive gemcitabine (1,000 mg/m2) and nab-paclitaxel (125 mg/m2 of body-surface area) weekly for 3 of 4 weeks or gemcitabine monotherapy (1,000 mg/m2 weekly for 7 of 8 weeks and then weekly for 3 of 4 weeks).

Sources: NCT00844649 · 7 · Level of evidence A1

Gemcitabine and nab-paclitaxel versus gemcitabine: A multicenter, international, phase III trial (NCT00844649) included 861 patients with metastatic pancreatic adenocarcinoma. Patients had a Karnofsky Performance Status of at least 70 and had not previously received chemotherapy for metastatic disease.[7][Level of evidence A1] Patients who received adjuvant gemcitabine or any other chemotherapy were excluded. The patients were randomly assigned to receive gemcitabine (1,000 mg/m2) and nab-paclitaxel (125 mg/m2 of body-surface area) weekly for 3 of 4 weeks or gemcitabine monotherapy (1,000 mg/m2 weekly for 7 of 8 weeks and then weekly for 3 of 4 weeks).

The median OS was 8.5 months in the nab-paclitaxel/gemcitabine group compared with 6.7 months in the gemcitabine group (HRdeath, 0.72; 95% CI, 0.62–0.83; P < .001).

Median PFS was 5.5 months in the nab-paclitaxel/gemcitabine group and 3.7 months in the gemcitabine group (HRdisease progression, 0.69; 95% CI, 0.58–0.82; P < .001).

Nab-paclitaxel/gemcitabine was more toxic than gemcitabine. The most common grade 3 toxicities in the nab-paclitaxel/gemcitabine group were neutropenia (38%), fatigue (17%), and neuropathy (17%); febrile neutropenia occurred in 3% of patients. In the gemcitabine-alone group, the most common grade 3 toxicities were neutropenia (27%), fatigue (1%), and neuropathy (1%); febrile neutropenia occurred in 1% of patients.

In the nab-paclitaxel/gemcitabine group, the median time from grade 3 neuropathy to grade 1 or resolution was 29 days. Of patients with grade 3 peripheral neuropathy, 44% were able to resume treatment at a reduced dose within a median of 23 days after onset of a grade 3 event.

Based on this trial, nab-paclitaxel/gemcitabine is a standard treatment option for patients with advanced pancreatic cancer.

Quality-of-life data were not measured for this regimen, and this study did not address the efficacy of nab-paclitaxel/gemcitabine versus FOLFIRINOX.

Gemcitabine versus 5-FU: Gemcitabine has demonstrated activity in patients with pancreatic cancer and is a useful palliative agent.[8-10] A phase III trial of gemcitabine versus 5-FU as first-line therapy in patients with advanced or metastatic adenocarcinoma of the pancreas reported a significant improvement in survival among patients treated with gemcitabine (the 1-year survival rate was 18% with gemcitabine compared with 2% with 5-FU; P = .003).[9][Level of evidence A1]

Sources: 8 · 10 · 9 · Level of evidence A1

Gemcitabine alone versus gemcitabine and erlotinib: The National Cancer Institute of Canada performed a phase III trial (CAN-NCIC-PA3 [NCT00026338]) that compared gemcitabine alone with the combination of gemcitabine and erlotinib (100 mg/d) in patients with advanced or metastatic pancreatic carcinomas.[11][Level of evidence A1]

Sources: CAN-NCIC-PA3 · 11 · Level of evidence A1

Gemcitabine alone versus gemcitabine and erlotinib: The National Cancer Institute of Canada performed a phase III trial (CAN-NCIC-PA3 [NCT00026338]) that compared gemcitabine alone with the combination of gemcitabine and erlotinib (100 mg/d) in patients with advanced or metastatic pancreatic carcinomas.[11][Level of evidence A1]

The addition of erlotinib modestly prolonged survival when combined with gemcitabine versus gemcitabine alone (HR, 0.81; 95% CI, 0.69–0.99; P = .038).

The median and 1-year survival rates for patients who received erlotinib were 6.2 months and 23%. The median and 1-year survival rates for patients who received placebo were 5.9 months and 17%.

Platinum analogue or fluoropyrimidine versus single-agent gemcitabine: Many phase III studies have evaluated a combination regimen with either a platinum analogue (cisplatin or oxaliplatin) or fluoropyrimidine versus single-agent gemcitabine.[12,13]

Sources: 12 · 13

Platinum analogue or fluoropyrimidine versus single-agent gemcitabine: Many phase III studies have evaluated a combination regimen with either a platinum analogue (cisplatin or oxaliplatin) or fluoropyrimidine versus single-agent gemcitabine.[12,13]

None of these phase III trials have demonstrated a statistically significant advantage favoring the use of combination chemotherapy in the first-line treatment of metastatic pancreatic cancer.

5-FU, leucovorin, and oxaliplatin (OFF regimen) versus best supportive care (BSC): Second-line chemotherapy after progression on a gemcitabine-based regimen may be beneficial. The Charité Onkologie (CONKO)-003 investigators randomly assigned patients requiring a second line of chemotherapy to either the OFF regimen or BSC.[14,15][Level of evidence C1] The OFF regimen consisted of leucovorin (200 mg/m2) followed by 5-FU (2,000 mg/m2 [24-hour continuous infusion] on days 1, 8, 15, and 22) and oxaliplatin (85 mg/m2 on days 8 and 22). After a rest of 3 weeks, the next cycle was started on day 43. The trial was terminated early because of poor accrual, and only 46 patients were randomly assigned to either the OFF regimen or BSC.

Sources: -003 · 14 · 15 · Level of evidence C1

5-FU, leucovorin, and oxaliplatin (OFF regimen) versus best supportive care (BSC): Second-line chemotherapy after progression on a gemcitabine-based regimen may be beneficial. The Charité Onkologie (CONKO)-003 investigators randomly assigned patients requiring a second line of chemotherapy to either the OFF regimen or BSC.[14,15][Level of evidence C1] The OFF regimen consisted of leucovorin (200 mg/m2) followed by 5-FU (2,000 mg/m2 [24-hour continuous infusion] on days 1, 8, 15, and 22) and oxaliplatin (85 mg/m2 on days 8 and 22). After a rest of 3 weeks, the next cycle was started on day 43. The trial was terminated early because of poor accrual, and only 46 patients were randomly assigned to either the OFF regimen or BSC.

The median survival was 4.82 months (95% CI, 4.29–5.35) with the OFF treatment regimen and 2.30 months (95% CI, 1.76–2.83) with BSC alone (HR, 0.45; 95% CI, 0.24–0.83).

Median OS was 9.09 months for the sequence of gemcitabine/OFF and 7.90 months for gemcitabine/BSC.

The early closure of the study and the very small number of patients made the P values misleading. Therefore, second-line chemotherapy with the OFF regimen may be falsely associated with improved survival.

Health professional · Treatment of Locally Advanced Pancreatic Cancer / Treatment Options for Locally Advanced Pancreatic Cancer

Chemoradiation therapy

Source: Pancreatic Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: February 12, 2025. Captured 2026-09-09.

The role of chemoradiation in locally advanced pancreatic cancer remains controversial. Table 7 summarizes phase III randomized studies of chemoradiation for locally advanced pancreatic cancer.

Sources: Table 7

Table 7. Randomized Studies in Locally Advanced Pancreatic Cancer: Median Survival
TrialRegimenChemoradiationRadiation AloneChemotherapy AloneP Value
5-FU = fluorouracil; ECOG = Eastern Cooperative Oncology Group; FFCD = Fédération Francophone de Cancérologie Digestive; GEM = gemcitabine; GITSG = Gastrointestinal Tumor Study Group; Gy = gray (unit of absorbed radiation of ionizing radiation); P value = probability value; XRT = radiation therapy.
Pre-2000
GITSG [16]Radiation alone vs. 5-FU/60 Gy XRT40 wk20 wk<.01
ECOG [17]Radiation vs. 5-FU, mitomycin C/59 Gy XRT8.4 mo7.1 mo.16
Post-2000
FFCD [18]GEM vs. GEM, cisplatin, 60 Gy XRT8.6 mo13 mo.03
ECOG [19]GEM vs. GEM/50.4 Gy XRT11.1 mo9.2 mo.017

Sources: 16 · 17 · 18 · 19

Evidence (chemoradiation therapy):

Three trials evaluated combined modality therapy versus radiation therapy alone.[16-18] The trials had substantial deficiencies in design or analysis. Initially, the standard of practice was to give chemoradiation therapy based on data from the first two studies. However, with the publication of the third study, standard practice changed to chemotherapy followed by chemoradiation in the absence of metastases.

Sources: 16 · 18

LAP07 (NCT00634725): The LAP07 study was an international, randomized, phase III study based on the results of the Groupe Coopérateur Multidisciplinaire en Oncologie (GERCOR) study. In total, 449 patients were enrolled between 2008 and 2011, with random assignment via a two-step randomization process. In the first step, patients were randomly assigned to induction gemcitabine (n = 223) or gemcitabine plus erlotinib (n = 219) for four cycles. For the second step, patients with controlled tumors were randomly assigned (n = 269) a second time to receive either chemotherapy (n = 136) or chemoradiation therapy (n = 133). A total dose of 54 Gy in 30 daily fractions was prescribed with concurrent capecitabine at a dose of 800 mg/m2 twice daily on days of radiation therapy.[20][Level of evidence A1]The LAP07 study represents the most robust, prospective, randomized phase III data regarding the role of chemoradiation therapy in the setting of gemcitabine-based induction chemotherapy that demonstrates no OS benefit. However, this study was initiated before the advent of FOLFIRINOX chemotherapy, which has been widely adopted into the locally advanced setting. The role of chemoradiation in the setting of more active chemotherapy regimens, including gemcitabine/paclitaxel and FOLFIRINOX, has yet to be evaluated.

Sources: LAP07 · 20 · Level of evidence A1

LAP07 (NCT00634725): The LAP07 study was an international, randomized, phase III study based on the results of the Groupe Coopérateur Multidisciplinaire en Oncologie (GERCOR) study. In total, 449 patients were enrolled between 2008 and 2011, with random assignment via a two-step randomization process. In the first step, patients were randomly assigned to induction gemcitabine (n = 223) or gemcitabine plus erlotinib (n = 219) for four cycles. For the second step, patients with controlled tumors were randomly assigned (n = 269) a second time to receive either chemotherapy (n = 136) or chemoradiation therapy (n = 133). A total dose of 54 Gy in 30 daily fractions was prescribed with concurrent capecitabine at a dose of 800 mg/m2 twice daily on days of radiation therapy.[20][Level of evidence A1]The LAP07 study represents the most robust, prospective, randomized phase III data regarding the role of chemoradiation therapy in the setting of gemcitabine-based induction chemotherapy that demonstrates no OS benefit. However, this study was initiated before the advent of FOLFIRINOX chemotherapy, which has been widely adopted into the locally advanced setting. The role of chemoradiation in the setting of more active chemotherapy regimens, including gemcitabine/paclitaxel and FOLFIRINOX, has yet to be evaluated.

The primary end point was OS. After interim analysis, the study was stopped early because of futility.

With a median follow-up of 36.7 months, the median OS from the date of the first randomization was not significantly different between chemotherapy at 16.5 months (95% CI, 14.5–18.5) and chemoradiation therapy at 15.2 months (95% CI, 13.9–17.3; P = .83).

Median OS after the first randomization was 13.6 months (95% CI, 12.3–15.3) for the patients who received gemcitabine and was 11.9 months (95% CI, 10.4–13.5; P = .09) for the patients who received gemcitabine plus erlotinib.

Gastrointestinal Tumor Study Group (GITSG) GITSG-9273 trial: Before 2000, several phase III trials evaluated combined modality therapy versus radiation therapy alone. Before the use of gemcitabine for patients with locally advanced or metastatic pancreatic cancer, investigators from the GITSG randomly assigned 106 patients with locally advanced pancreatic adenocarcinoma to receive external-beam radiation therapy (EBRT) (60 Gy) alone or concurrent EBRT (either 40 Gy or 60 Gy) plus bolus 5-FU.[16][Level of evidence A1]

Sources: 16 · Level of evidence A1

Gastrointestinal Tumor Study Group (GITSG) GITSG-9273 trial: Before 2000, several phase III trials evaluated combined modality therapy versus radiation therapy alone. Before the use of gemcitabine for patients with locally advanced or metastatic pancreatic cancer, investigators from the GITSG randomly assigned 106 patients with locally advanced pancreatic adenocarcinoma to receive external-beam radiation therapy (EBRT) (60 Gy) alone or concurrent EBRT (either 40 Gy or 60 Gy) plus bolus 5-FU.[16][Level of evidence A1]

The study was stopped early when the chemoradiation therapy groups were found to have better efficacy. The 1-year survival rate was 11% for patients who received EBRT alone compared with 38% for patients who received chemoradiation therapy with 40 Gy and 36% for patients who received chemoradiation therapy with 60 Gy.

After an additional 88 patients were enrolled in the combined modality arms, there was a trend toward improved survival with 60 Gy EBRT plus 5-FU, but the difference in time-to-progression and OS was not statistically significant when compared with the 40 Gy arm.[21]

Sources: 21

ECOG E-8282 trial: Investigators from the ECOG randomly assigned 114 patients to receive radiation therapy (59.4 Gy) alone or with concurrent infusional 5-FU (1,000 mg/m2/d on days 2–5 and 28–31) plus mitomycin (10 mg/m2 on day 2).[17]

Sources: 17

ECOG E-8282 trial: Investigators from the ECOG randomly assigned 114 patients to receive radiation therapy (59.4 Gy) alone or with concurrent infusional 5-FU (1,000 mg/m2/d on days 2–5 and 28–31) plus mitomycin (10 mg/m2 on day 2).[17]

The trial reported no difference in OS between the two groups.

Fédération Francophone de Cancérologie Digestive–Société Française de Radiothérapie Oncologie (FFCD-SFRO) trial: As it became clear that radiation therapy alone was an inadequate treatment, investigators evaluated combined modality approaches versus chemotherapy alone. Investigators from the FFCD-SFRO randomly assigned 119 patients to induction chemoradiation therapy (60 Gy in 2 Gy fractions with 300 mg/m2/d of continuous-infusion 5-FU on days 1–5 for 6 weeks and 20 mg/m2/d of cisplatin on days 1–5 during weeks 1 and 5) or induction gemcitabine (1,000 mg/m2 weekly for 7 weeks). Maintenance gemcitabine was administered to both groups until stopped by disease progression or treatment discontinuation as a result of toxicity.[22][Level of evidence A1]

Sources: 22 · Level of evidence A1

Fédération Francophone de Cancérologie Digestive–Société Française de Radiothérapie Oncologie (FFCD-SFRO) trial: As it became clear that radiation therapy alone was an inadequate treatment, investigators evaluated combined modality approaches versus chemotherapy alone. Investigators from the FFCD-SFRO randomly assigned 119 patients to induction chemoradiation therapy (60 Gy in 2 Gy fractions with 300 mg/m2/d of continuous-infusion 5-FU on days 1–5 for 6 weeks and 20 mg/m2/d of cisplatin on days 1–5 during weeks 1 and 5) or induction gemcitabine (1,000 mg/m2 weekly for 7 weeks). Maintenance gemcitabine was administered to both groups until stopped by disease progression or treatment discontinuation as a result of toxicity.[22][Level of evidence A1]

Median survival was superior in the gemcitabine group (13 vs. 8.6 months; P = .03).

Nonhematological grade 3 to 4 toxicities (primarily gastrointestinal) were significantly more common in the chemoradiation therapy group (44% vs. 18%; P = .004), and fewer patients completed at least 75% of induction therapy (42% vs. 73%).

Nonetheless, the survival benefit persisted in a per-protocol analysis of patients receiving at least 75% of planned therapy. Notably, the dose intensity of maintenance gemcitabine was significantly less in the chemoradiation therapy group because of a greater incidence of grades 3 to 4 hematological toxicities (71% vs. 27%; P = .0001).

As a result of this study, giving induction chemoradiation therapy has lost support.

ECOG: The results of the FFCD-SFRO study counter the results of a study from ECOG in which investigators randomly assigned 74 patients to either gemcitabine alone or gemcitabine with radiation followed by gemcitabine.[19] Of note, the study was closed early as the result of poor accrual.

Sources: 19

ECOG: The results of the FFCD-SFRO study counter the results of a study from ECOG in which investigators randomly assigned 74 patients to either gemcitabine alone or gemcitabine with radiation followed by gemcitabine.[19] Of note, the study was closed early as the result of poor accrual.

The primary end point was survival, which was 9.2 months (95% CI, 7.9–11.4) for chemotherapy and 11.1 months (95% CI, 7.6–15.5) for combined modality therapy (one-sided P = .017 by stratified log-rank test).

Grades 4 and 5 toxicity were greater in the chemoradiation therapy arm than in the chemotherapy arm (41% vs. 9%).

GERCOR: Given the increased toxicity of chemoradiation therapy and the early development of metastatic disease in a large percentage of patients with locally advanced pancreatic cancer, investigators are pursuing a strategy of selecting patients with localized disease for chemoradiation therapy. With this strategy, the selected patients have an absence of progressive disease locally or systemically after several months of chemotherapy.[23][Level of evidence C1]

Sources: 23 · Level of evidence C1

GERCOR: Given the increased toxicity of chemoradiation therapy and the early development of metastatic disease in a large percentage of patients with locally advanced pancreatic cancer, investigators are pursuing a strategy of selecting patients with localized disease for chemoradiation therapy. With this strategy, the selected patients have an absence of progressive disease locally or systemically after several months of chemotherapy.[23][Level of evidence C1]

A retrospective analysis of 181 patients enrolled in prospective phase II and III GERCOR studies revealed that 29% had metastatic disease after 3 months of gemcitabine-based chemotherapy.

For the remaining 71%, median OS was significantly longer among patients treated with chemoradiation therapy than among patients treated with additional chemotherapy (15.0 months vs. 11.7 months; P = .0009).

Health professional · Treatment of Locally Advanced Pancreatic Cancer / Treatment Options for Locally Advanced Pancreatic Cancer

Surgery

Source: Pancreatic Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: February 12, 2025. Captured 2026-09-09.

Patients with locally advanced pancreatic cancer have tumors that are technically unresectable because of local vessel impingement or invasion by tumor. However, with the combination of chemotherapy and chemoradiation therapy, some patients may become candidates for radical pancreatic resection.

Health professional · Treatment of Locally Advanced Pancreatic Cancer / Treatment Options for Locally Advanced Pancreatic Cancer

Palliative surgery

Source: Pancreatic Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: February 12, 2025. Captured 2026-09-09.

A significant proportion (approximately one-third) of patients with pancreatic cancer present with locally advanced disease. Patients may benefit from palliation of biliary obstruction by endoscopic, surgical, or radiological means.[24]

Sources: 24

Health professional

Treatment of Metastatic or Recurrent Pancreatic Cancer

Source: Pancreatic Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: February 12, 2025. Captured 2026-09-09.

Health professional · Treatment of Metastatic or Recurrent Pancreatic Cancer

Treatment Options for Metastatic or Recurrent Pancreatic Cancer

Source: Pancreatic Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: February 12, 2025. Captured 2026-09-09.

Treatment options for metastatic or recurrent pancreatic cancer include:

Chemotherapy with or without targeted therapy.

Sources: Chemotherapy with or without targeted therapy

Clinical trials evaluating new anticancer agents alone or in combination with chemotherapy.

Palliative therapies can be considered in patients with any stage of disease. For more information, see the Palliative Therapy section.

Sources: Palliative Therapy

Health professional · Treatment of Metastatic or Recurrent Pancreatic Cancer / Treatment Options for Metastatic or Recurrent Pancreatic Cancer

Chemotherapy with or without targeted therapy

Source: Pancreatic Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: February 12, 2025. Captured 2026-09-09.

Because of the low objective response rate and limited efficacy of palliative chemotherapy regimens, all newly diagnosed patients should consider enrolling in clinical trials. Multiagent chemotherapy combinations have been shown to prolong outcomes compared with single-agent gemcitabine.[1-3]

Sources: 1 · 3

Evidence (single-agent chemotherapy):

Gemcitabine versus fluorouracil (5-FU): A phase III trial of gemcitabine versus 5-FU as first-line therapy in patients with advanced or metastatic adenocarcinoma of the pancreas reported a significant improvement in survival among patients treated with gemcitabine (the 1-year survival rate was 18% with gemcitabine vs. 2% with 5-FU; P = .003).[1][Level of evidence A1]

Sources: 1 · Level of evidence A1

Evidence (multiagent chemotherapy):

FOLFIRINOX (leucovorin, 5-FU, irinotecan, and oxaliplatin) versus gemcitabine: A multicenter phase II/III trial included 342 patients with metastatic pancreatic adenocarcinoma with an Eastern Cooperative Oncology Group performance status score of 0 or 1.[4][Level of evidence A1] The patients were randomly assigned to receive FOLFIRINOX (oxaliplatin [85 mg/m2], irinotecan [180 mg/m2], leucovorin [400 mg/m2], and 5-FU [400 mg/m2] given as a bolus followed by 2,400 mg/m2 given as a 46-hour continuous infusion, every 2 weeks) or gemcitabine (1,000 mg/m2 weekly for 7 of 8 weeks and then weekly for 3 of 4 weeks).

Sources: 4 · Level of evidence A1

FOLFIRINOX (leucovorin, 5-FU, irinotecan, and oxaliplatin) versus gemcitabine: A multicenter phase II/III trial included 342 patients with metastatic pancreatic adenocarcinoma with an Eastern Cooperative Oncology Group performance status score of 0 or 1.[4][Level of evidence A1] The patients were randomly assigned to receive FOLFIRINOX (oxaliplatin [85 mg/m2], irinotecan [180 mg/m2], leucovorin [400 mg/m2], and 5-FU [400 mg/m2] given as a bolus followed by 2,400 mg/m2 given as a 46-hour continuous infusion, every 2 weeks) or gemcitabine (1,000 mg/m2 weekly for 7 of 8 weeks and then weekly for 3 of 4 weeks).

The median overall survival (OS) was 11.1 months in the FOLFIRINOX group compared with 6.8 months in the gemcitabine group (hazard ratio [HR]death, 0.57; 95% confidence interval [CI], 0.45–0.73; P < .001).

Median progression-free survival (PFS) was 6.4 months in the FOLFIRINOX group and 3.3 months in the gemcitabine group (HR for disease progression, 0.47; 95% CI, 0.37–0.59; P < .001).

FOLFIRINOX was more toxic than gemcitabine; 5.4% of patients in this group had febrile neutropenia. At 6 months, 31% of the patients in the FOLFIRINOX group had a definitive degradation of quality of life versus 66% in the gemcitabine group (HR, 0.47; 95% CI, 0.30–0.70; P < .001).

Based on this trial, FOLFIRINOX is considered a standard treatment option for patients with advanced pancreatic cancer.

NALIRIFOX (5-FU, irinotecan sucrosofate [also called nanoliposomal irinotecan], and oxaliplatin) versus gemcitabine and nab-paclitaxel: The multicenter, open-label, phase III NAPOLI 3 study (NCT04083235) included 770 patients with confirmed pancreatic ductal adenocarcinoma who had not been treated previously for metastatic disease. The patients were randomly assigned 1:1 to receive NALIRIFOX (irinotecan sucrosofate [50 mg/m2], oxaliplatin [60 mg/m2], leucovorin [400 mg/m2], and 5-FU [2,400 mg/m2] as an intravenous infusion over 46 hours on days 1 and 15 of cycles lasting 28 days) or nab-paclitaxel (125 mg/m2) and gemcitabine (1,000 mg/m2 given intravenously on days 1, 8, and 15 of cycles lasting 28 days). The primary end point was OS from randomization to death due to any cause, for NALIRIFOX versus gemcitabine/nab-paclitaxel. Secondary end points included PFS and overall response rate by RECIST version 1.1.[5]Based on this trial, NALIRIFOX is a standard first-line treatment option for patients with advanced pancreatic cancer.

Sources: NAPOLI 3 · 5

NALIRIFOX (5-FU, irinotecan sucrosofate [also called nanoliposomal irinotecan], and oxaliplatin) versus gemcitabine and nab-paclitaxel: The multicenter, open-label, phase III NAPOLI 3 study (NCT04083235) included 770 patients with confirmed pancreatic ductal adenocarcinoma who had not been treated previously for metastatic disease. The patients were randomly assigned 1:1 to receive NALIRIFOX (irinotecan sucrosofate [50 mg/m2], oxaliplatin [60 mg/m2], leucovorin [400 mg/m2], and 5-FU [2,400 mg/m2] as an intravenous infusion over 46 hours on days 1 and 15 of cycles lasting 28 days) or nab-paclitaxel (125 mg/m2) and gemcitabine (1,000 mg/m2 given intravenously on days 1, 8, and 15 of cycles lasting 28 days). The primary end point was OS from randomization to death due to any cause, for NALIRIFOX versus gemcitabine/nab-paclitaxel. Secondary end points included PFS and overall response rate by RECIST version 1.1.[5]Based on this trial, NALIRIFOX is a standard first-line treatment option for patients with advanced pancreatic cancer.

The median OS was 11.1 months (95% CI, 10.0–12.1) in the NALIRIFOX group and 9.2 months (95% CI, 8.3–10.6) in the nab-paclitaxel/gemcitabine group (HR, 0.83; 95% CI, 0.7–0.99; P = .036). The median follow-up was 16.1 months.[5][Level of evidence A1]

Sources: 5 · Level of evidence A1

The median PFS was 7.4 months in the NALIRIFOX group and 5.6 months in the nab-paclitaxel/gemcitabine group (HR, 0.69; 95% CI, 0.58–0.83; P < .0001).

The overall response rate was 42% in the NALIRIFOX group and 36% in the nab-paclitaxel/gemcitabine group (P = .11). The median duration of response was 7.3 months in the NALIRIFOX group and 5 months in the nab-paclitaxel/gemcitabine group (HR, 0.67; 95% CI, 0.48–0.93).

There were 369 patients (>99%) with any adverse event in the NALIRIFOX group and 376 patients (99%) with any adverse event in the nab-paclitaxel/gemcitabine group. The most common grade 3 to 4 toxicities in the NALIRIFOX group were diarrhea (20%), hypokalemia (15%), neutropenia (14%), and nausea (12%). The most common grade 3 to 4 toxicities in the nab-paclitaxel/gemcitabine group were neutropenia (25%) and anemia (17%). Of note, hematological toxicities (i.e., neutropenia, anemia, thrombocytopenia) were lower in the NALIRIFOX group than the nab-paclitaxel/gemcitabine group. Peripheral neuropathy was noted in 3% of patients in the NALIRIFOX group compared with 6% of patients in the gemcitabine/nab-paclitaxel group.

Gemcitabine and nab-paclitaxel versus gemcitabine: A multicenter, international, phase III trial (NCT00844649) included 861 patients with metastatic pancreatic adenocarcinoma. Patients had a Karnofsky Performance Status of at least 70 and had not previously received chemotherapy for metastatic disease.[6][Level of evidence A1] Patients who received adjuvant gemcitabine or any other chemotherapy were excluded. The patients were randomly assigned to receive gemcitabine (1,000 mg/m2) and nab-paclitaxel (125 mg/m2 of body-surface area) weekly for 3 of 4 weeks or gemcitabine monotherapy (1,000 mg/m2 weekly for 7 of 8 weeks and then weekly for 3 of 4 weeks).

Sources: NCT00844649 · 6 · Level of evidence A1

Gemcitabine and nab-paclitaxel versus gemcitabine: A multicenter, international, phase III trial (NCT00844649) included 861 patients with metastatic pancreatic adenocarcinoma. Patients had a Karnofsky Performance Status of at least 70 and had not previously received chemotherapy for metastatic disease.[6][Level of evidence A1] Patients who received adjuvant gemcitabine or any other chemotherapy were excluded. The patients were randomly assigned to receive gemcitabine (1,000 mg/m2) and nab-paclitaxel (125 mg/m2 of body-surface area) weekly for 3 of 4 weeks or gemcitabine monotherapy (1,000 mg/m2 weekly for 7 of 8 weeks and then weekly for 3 of 4 weeks).

The median OS was 8.5 months in the nab-paclitaxel/gemcitabine group compared with 6.7 months in the gemcitabine group (HRdeath, 0.72; 95% CI, 0.62–0.83; P < .001).

Median PFS was 5.5 months in the nab-paclitaxel/gemcitabine group and 3.7 months in the gemcitabine group (HRdisease progression, 0.69; 95% CI, 0.58–0.82; P < .001).

Nab-paclitaxel/gemcitabine was more toxic than gemcitabine. The most common grade 3 toxicities in the nab-paclitaxel/gemcitabine group were neutropenia (38%), fatigue (17%), and neuropathy (17%); febrile neutropenia occurred in 3% of patients. In the gemcitabine-alone group, the most common grade 3 toxicities were neutropenia (27%), fatigue (1%), and neuropathy (1%); febrile neutropenia occurred in 1% of patients.

In the nab-paclitaxel/gemcitabine group, the median time from grade 3 neuropathy to grade 1 neuropathy or resolution was 29 days. Of patients with grade 3 peripheral neuropathy, 44% were able to resume treatment at a reduced dose within a median of 23 days after onset of a grade 3 event.

Based on this trial, nab-paclitaxel plus gemcitabine is a standard treatment option for patients with advanced pancreatic cancer.

Quality-of-life data were not measured for this regimen, and this study did not address the efficacy of nab-paclitaxel/gemcitabine versus FOLFIRINOX.

Gemcitabine alone versus gemcitabine and erlotinib: The National Cancer Institute of Canada performed a phase III trial (CAN-NCIC-PA3 [NCT00026338]) that compared gemcitabine alone with the combination of gemcitabine and erlotinib (100 mg/d) in patients with advanced or metastatic pancreatic carcinomas.[7][Level of evidence A1]

Sources: CAN-NCIC-PA3 · 7 · Level of evidence A1

Gemcitabine alone versus gemcitabine and erlotinib: The National Cancer Institute of Canada performed a phase III trial (CAN-NCIC-PA3 [NCT00026338]) that compared gemcitabine alone with the combination of gemcitabine and erlotinib (100 mg/d) in patients with advanced or metastatic pancreatic carcinomas.[7][Level of evidence A1]

The addition of erlotinib modestly prolonged survival when combined with gemcitabine alone (HR, 0.81; 95% CI, 0.69–0.99; P = .038).

The corresponding median survival rate for patients receiving erlotinib was 6.2 months versus 5.9 months for patients receiving placebo. The 1-year survival rate for patients receiving erlotinib was 23% versus 17% for patients receiving placebo.

Evidence (second-line chemotherapy):

Irinotecan sucrosofate with or without 5-FU and leucovorin: The NAPOLI-1 trial (NCT01494506) evaluated the role of irinotecan sucrosofate in patients with metastatic pancreatic cancer who were previously treated with gemcitabine-based therapies.[8] Irinotecan sucrosofate is an encapsulated formulation of irinotecan designed to increase intratumoral levels of irinotecan and its active metabolite. In this study, a total of 417 patients were randomly assigned to receive either irinotecan sucrosofate monotherapy (120 mg/m2 every 3 weeks; n = 151), 5-FU and leucovorin (n = 149), or irinotecan sucrosofate (80 mg/m2 every 2 weeks plus 5-FU) and leucovorin (n = 117).[8][Level of evidence B1]

Sources: NAPOLI-1 · 8 · 8 · Level of evidence B1

Irinotecan sucrosofate with or without 5-FU and leucovorin: The NAPOLI-1 trial (NCT01494506) evaluated the role of irinotecan sucrosofate in patients with metastatic pancreatic cancer who were previously treated with gemcitabine-based therapies.[8] Irinotecan sucrosofate is an encapsulated formulation of irinotecan designed to increase intratumoral levels of irinotecan and its active metabolite. In this study, a total of 417 patients were randomly assigned to receive either irinotecan sucrosofate monotherapy (120 mg/m2 every 3 weeks; n = 151), 5-FU and leucovorin (n = 149), or irinotecan sucrosofate (80 mg/m2 every 2 weeks plus 5-FU) and leucovorin (n = 117).[8][Level of evidence B1]

Median OS was 6.1 months (95% CI, 4.8–8.9) in patients who received irinotecan sucrosofate with 5-FU and 4.2 months (95% CI, 3.6–4.9) in patients who received 5-FU and leucovorin (P = .012). Median OS was 4.9 months (95% CI, 4.2–5.6) for patients who received irinotecan sucrosofate monotherapy, compared with 4.2 months (95% CI, 3.6–4.9) for those who received 5-FU and leucovorin (unstratified HR, 0.99; P = .94). On multivariate analysis, irinotecan sucrosofate plus 5-FU and leucovorin was associated with improved OS (HR, 0.58; 95% CI, 0.42–0.81).

Grade 3 or 4 adverse events occurred most frequently in the patients who received irinotecan sucrosofate plus 5-FU and leucovorin and included neutropenia (27%), diarrhea (13%), vomiting (11%), and fatigue (14%).

Despite differences in survival and toxicity between regimens, quality of life was not significantly different between treatment groups.

The benefit of using irinotecan sucrosofate rather than unencapsulated irinotecan has not been established because the regimen for the control arm of this study was 5-FU/leucovorin. Additionally, the value of using irinotecan sucrosofate after FOLFIRINOX in the first-line setting is not clear.

5-FU, leucovorin, and oxaliplatin (OFF regimen) versus best supportive care (BSC): Second-line chemotherapy after progression on a gemcitabine-based regimen may be beneficial. The Charité Onkologie (CONKO)-003 investigators randomly assigned patients requiring a second line of chemotherapy to either an OFF regimen or BSC.[2]; [3][Level of evidence C1] The OFF regimen consisted of leucovorin (200 mg/m2) followed by 5-FU (2,000 mg/m2 [24 hours continuous infusion] on days 1, 8, 15, and 22) and oxaliplatin (85 mg/m2 on days 8 and 22). After a rest of 3 weeks, the next cycle was started on day 43. The trial was terminated early because of poor accrual, and only 46 patients were randomly assigned to either the OFF regimen or BSC.

Sources: (CONKO)-003 · 2 · 3 · Level of evidence C1

5-FU, leucovorin, and oxaliplatin (OFF regimen) versus best supportive care (BSC): Second-line chemotherapy after progression on a gemcitabine-based regimen may be beneficial. The Charité Onkologie (CONKO)-003 investigators randomly assigned patients requiring a second line of chemotherapy to either an OFF regimen or BSC.[2]; [3][Level of evidence C1] The OFF regimen consisted of leucovorin (200 mg/m2) followed by 5-FU (2,000 mg/m2 [24 hours continuous infusion] on days 1, 8, 15, and 22) and oxaliplatin (85 mg/m2 on days 8 and 22). After a rest of 3 weeks, the next cycle was started on day 43. The trial was terminated early because of poor accrual, and only 46 patients were randomly assigned to either the OFF regimen or BSC.

The median survival was 4.82 months (95% CI, 4.29–5.35) with the OFF treatment regimen and 2.30 months (95% CI, 1.76–2.83) with BSC alone (HR, 0.45; 95% CI, 0.24–0.83).

Median OS was 9.09 months for the sequence of gemcitabine/OFF and 7.90 months for gemcitabine/BSC.

The early closure of the study and the very small number of patients made the P values misleading. Therefore, second-line chemotherapy with the OFF regimen may be falsely associated with improved survival.

FOLFOX (leucovorin, 5-FU, and oxaliplatin) versus 5-FU/leucovorin after gemcitabine chemotherapy: The prospective, multicenter PANCREOX trial included 108 patients with advanced pancreatic cancer who had previously received first-line gemcitabine-based chemotherapy. Patients were randomly assigned to receive 5-FU/leucovorin without oxaliplatin (n = 54) or with oxaliplatin (n = 54), administered as modified FOLFOX-6 (mFOLFOX-6).[9][Level of evidence C1] With a target accrual of 128 patients, the study closed prematurely because of slow accrual.

Sources: 9 · Level of evidence C1

FOLFOX (leucovorin, 5-FU, and oxaliplatin) versus 5-FU/leucovorin after gemcitabine chemotherapy: The prospective, multicenter PANCREOX trial included 108 patients with advanced pancreatic cancer who had previously received first-line gemcitabine-based chemotherapy. Patients were randomly assigned to receive 5-FU/leucovorin without oxaliplatin (n = 54) or with oxaliplatin (n = 54), administered as modified FOLFOX-6 (mFOLFOX-6).[9][Level of evidence C1] With a target accrual of 128 patients, the study closed prematurely because of slow accrual.

After a median follow-up of 8.8 months, the median PFS was 3.1 months in the mFOLFOX-6 arm and 2.9 months in the infusional 5-FU arm (HR, 1.00; 95% CI, 0.66–1.53, P = .989).

Overall response rate and quality of life was not significantly different in the two arms.

The overall incidence of grade 3 or 4 adverse events was 63% in the mFOLFOX-6 arm and 11% in the 5-FU/leucovorin arm. However, more patients in the mFOLFOX-6 arm withdrew from the study because of adverse events than did patients in the 5-FU/leucovorin arm (20% vs. 2%).

Based on this study, no benefit was seen with the addition of oxaliplatin, administered in the mFOLFOX-6 regimen, versus infusional 5-FU/leucovorin among patients with advanced pancreatic cancer after first-line gemcitabine-based chemotherapy. These results may suggest that oxaliplatin-based regimens for metastatic pancreatic cancer may yield the greatest benefit in the first-line setting.

Gemcitabine/paclitaxel versus gemcitabine after FOLFIRINOX failure or intolerance: The prospective, open-label, phase III GEMPAX study (NCT03943667) included 211 patients with metastatic pancreatic cancer that progressed during or within 3 months of completing first-line FOLFIRINOX (including FOLFIRINOX treatment as adjuvant therapy) or were intolerant of this therapy. Patients were randomly assigned to one of the following treatment arms:[10]The following results were observed:

Sources: GEMPAX · 10

Gemcitabine/paclitaxel versus gemcitabine after FOLFIRINOX failure or intolerance: The prospective, open-label, phase III GEMPAX study (NCT03943667) included 211 patients with metastatic pancreatic cancer that progressed during or within 3 months of completing first-line FOLFIRINOX (including FOLFIRINOX treatment as adjuvant therapy) or were intolerant of this therapy. Patients were randomly assigned to one of the following treatment arms:[10]The following results were observed:

Gemcitabine/paclitaxel: Gemcitabine (1,000 mg/m2) and solvent-based paclitaxel (80 mg/m2) on days 1, 8, and 15 of a 28-day cycle.

Gemcitabine alone: Gemcitabine (1,000 mg/m2) on days 1, 8, and 15 of a 29-day cycle.

There was no significant difference in OS among patients who received gemcitabine/paclitaxel (6.4 months after a median follow-up of 13.4 months) or gemcitabine alone (5.9 months after 13.8 months of follow-up) (HR, 0.87; 95% CI, 0.63–1.20; P = .4095). However, OS was improved in the following subgroups of patients who received gemcitabine/paclitaxel: (1) patients aged 65 years or younger (HR, 0.66; 95% CI, 0.44–0.99), and (2) patients with CA 19-9 levels of 59 times the upper limit of normal or higher at baseline (HR, 0.64; 95% CI, 0.42–0.97).[10][Level of evidence B1]

Sources: 10 · Level of evidence B1

PFS was 3.1 months in the gemcitabine/paclitaxel group and 2.0 months in the gemcitabine-alone group (HR, 0.64; 95% CI, 0.47–0.89, P = .0067). The objective response rate was 17.1% in the gemcitabine/paclitaxel group and 4.2% in the gemcitabine-alone group (P = .008).

Third-line therapies were given to 32.1% of patients in the gemcitabine/paclitaxel group and 46.5% of patients in the gemcitabine-alone group.

The overall incidence of grade 3 or greater treatment-related adverse events was 58% in the gemcitabine/paclitaxel group and 27.1% in the gemcitabine-alone group. In the gemcitabine/paclitaxel group, 13% of patients experienced serious treatment-related adverse events, versus 7.1% of patients in the gemcitabine-alone group. The most common grade 3 or greater treatment-related adverse events among patients in the gemcitabine/paclitaxel group versus those in the gemcitabine-alone group were anemia (15.2% vs. 4.3%), thrombocytopenia (19.6% vs. 4.3%), neutropenia (15.9% vs. 15.7%), peripheral neuropathy (12.3% vs. 0%), and asthenia (10.1% vs. 2.9%). There was one grade 5 adverse event associated with gemcitabine/paclitaxel therapy, which was attributed as acute respiratory distress.

Based on this study, no OS benefit was seen with second-line gemcitabine/paclitaxel over gemcitabine alone. However, there was an OS benefit in certain subgroups (patients aged 65 years or younger and patients with high CA 19-9 levels at baseline). PFS and objective response rate were significantly higher in the gemcitabine/paclitaxel group. Thus, combination therapy with gemcitabine/paclitaxel can be considered for the appropriate patient, recognizing the higher rate of treatment-related adverse events.

Health professional · Treatment of Metastatic or Recurrent Pancreatic Cancer / Treatment Options for Metastatic or Recurrent Pancreatic Cancer

Special considerations for patients with germline BRCA1/BRCA2 variants

Source: Pancreatic Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: February 12, 2025. Captured 2026-09-09.

Germline variants in BRCA1 or BRCA2 are present in 4% to 8% of patients with pancreatic adenocarcinoma.[11,12] BRCA1/BRCA2 encode for proteins in the homologous repair pathway and DNA double-stranded break repair, and thus may be more sensitive to further DNA damage. Pancreatic tumors with BRCA1/BRCA2 variants demonstrate improved responses to platinum-based therapies.[13] Poly (ADP-ribose) polymerase (PARP) inhibition has been posited to act synergistically with BRCA1/BRCA2 variants by inhibiting single-stranded break repair. Several PARP inhibitors have been approved for treatment of patients with BRCA1/BRCA2-mutated advanced ovarian and breast cancers and are actively being studied for the management of patients with BRCA1/BRCA2-mutated pancreatic adenocarcinoma.

Sources: 11 · 12 · 13

Health professional · Treatment of Metastatic or Recurrent Pancreatic Cancer / Treatment Options for Metastatic or Recurrent Pancreatic Cancer / Special considerations for patients with germline BRCA1/BRCA2 variants

Olaparib

Source: Pancreatic Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: February 12, 2025. Captured 2026-09-09.

Olaparib (a PARP inhibitor) maintenance therapy can be considered for patients with germline BRCA1/BRCA2 variants and metastatic pancreatic adenocarcinoma who have responded to first-line platinum-based therapy for more than 4 months.

Evidence (olaparib):

POLO trial (NCT02184195): A multicenter, phase III, randomized, double-blind, placebo-controlled trial that included 154 patients with metastatic pancreatic adenocarcinoma with germline BRCA1 or BRCA2 variants whose disease had not progressed after 16 weeks of first-line platinum-based chemotherapy.[14][Level of evidence B1] The patients were assigned 3:2 to receive olaparib (300 mg twice daily) or placebo and were assessed for PFS.

Sources: POLO · 14 · Level of evidence B1

POLO trial (NCT02184195): A multicenter, phase III, randomized, double-blind, placebo-controlled trial that included 154 patients with metastatic pancreatic adenocarcinoma with germline BRCA1 or BRCA2 variants whose disease had not progressed after 16 weeks of first-line platinum-based chemotherapy.[14][Level of evidence B1] The patients were assigned 3:2 to receive olaparib (300 mg twice daily) or placebo and were assessed for PFS.

Of 3,315 patients screened, 247 patients were identified with germline BRCA variants.

The median PFS was 7.4 months in the olaparib arm and 3.8 months in the placebo arm (HR, 0.53; 95% CI, 0.35‒0.82; P = .004)

Median OS was 18.9 months in the olaparib group and 18.1 months in the placebo arm (HR, 0.91; 95% CI, 0.56‒1.46; P = .68).

There were more grade 3 or 4 treatment-related adverse events with olaparib (40%) compared with placebo (23%).

Health professional

Palliative Therapy

Source: Pancreatic Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: February 12, 2025. Captured 2026-09-09.

Palliative therapy options for patients with pancreatic cancer include:

Palliative surgical bypass procedures such as endoscopic or radiologically placed stents.[1,2]

Sources: 1 · 2

Palliative radiation procedures.

Pain relief by celiac axis nerve or intrapleural block (percutaneous).[3]

Sources: 3

Other palliative medical care alone.

For patients · General Information About Pancreatic Cancer

Certain factors affect prognosis (chance of recovery) and treatment options.

Source: Pancreatic Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: July 8, 2026. Captured 2026-09-09.

The prognosis and treatment options depend on:

whether the tumor can be removed by surgery

the stage of the cancer (the size of the tumor and whether the cancer has spread outside the pancreas to nearby tissues or lymph nodes or to other places in the body)

Sources: lymph nodes

the patient’s general health

whether the cancer has just been diagnosed or has recurred (come back)

Pancreatic cancer can be controlled only if it is found before it has spread, when it can be completely removed by surgery. If the cancer has spread, palliative treatment can improve the patient's quality of life by controlling the symptoms and complications of this disease.

Sources: palliative treatment · quality of life

For patients · Stages of Pancreatic Cancer

The following groups are used to plan treatment:

Source: Pancreatic Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: July 8, 2026. Captured 2026-09-09.

For patients · Stages of Pancreatic Cancer / The following groups are used to plan treatment:

Resectable pancreatic cancer

Source: Pancreatic Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: July 8, 2026. Captured 2026-09-09.

Resectable pancreatic cancer can be removed by surgery because it has not grown into major blood vessels near the tumor.

For patients · Stages of Pancreatic Cancer / The following groups are used to plan treatment:

Borderline resectable pancreatic cancer

Source: Pancreatic Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: July 8, 2026. Captured 2026-09-09.

Borderline resectable pancreatic cancer has grown into a major blood vessel or nearby tissue or organs. It may be possible to remove the tumor, but there is a high risk that all of the cancer cells will not be removed with surgery.

For patients · Stages of Pancreatic Cancer / The following groups are used to plan treatment:

Locally advanced pancreatic cancer

Source: Pancreatic Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: July 8, 2026. Captured 2026-09-09.

Locally advanced pancreatic cancer has grown into or close to nearby lymph nodes or blood vessels, so surgery cannot completely remove the cancer.

Sources: Locally advanced

For patients · Stages of Pancreatic Cancer / The following groups are used to plan treatment:

Metastatic pancreatic cancer

Source: Pancreatic Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: July 8, 2026. Captured 2026-09-09.

Metastatic pancreatic cancer has spread to other organs, so surgery cannot completely remove the cancer.

Sources: Metastatic

For patients · Stages of Pancreatic Cancer / The following groups are used to plan treatment:

Recurrent pancreatic cancer

Source: Pancreatic Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: July 8, 2026. Captured 2026-09-09.

Recurrent pancreatic cancer is cancer that has recurred (come back) after it has been treated. The cancer may come back in the pancreas or in other parts of the body. Tests will be done to help determine where the cancer has returned in your body. The type of treatment for recurrent pancreatic cancer will depend on where it has come back.

Learn more in Recurrent Cancer: When Cancer Comes Back.

Sources: Recurrent Cancer: When Cancer Comes Back

For patients

Treatment Option Overview

Source: Pancreatic Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: July 8, 2026. Captured 2026-09-09.

For patients · Treatment Option Overview

Key Points

Source: Pancreatic Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: July 8, 2026. Captured 2026-09-09.

There are different types of treatment for patients with pancreatic cancer.

The following types of treatment are used:

The following types of treatment are used:

Surgery

Radiation therapy

Chemotherapy

Chemoradiation therapy

Targeted therapy

There are treatments for pain caused by pancreatic cancer.

Patients with pancreatic cancer have special nutritional needs.

New types of treatment are being tested in clinical trials.

Treatment for pancreatic cancer may cause side effects.

Follow-up care may be needed.

For patients · Treatment Option Overview

There are different types of treatment for patients with pancreatic cancer.

Source: Pancreatic Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: July 8, 2026. Captured 2026-09-09.

Different types of treatments are available for people with pancreatic cancer. You and your cancer care team will work together to decide your treatment plan, which may include more than one type of treatment. Many factors will be considered, such as the stage of the cancer, your overall health, and your preferences. Your plan will include information about your cancer, the goals of treatment, your treatment options and the possible side effects, and the expected length of treatment.

Talking with your cancer care team before treatment begins about what to expect will be helpful. You’ll want to learn what you need to do before treatment begins, how you’ll feel while going through it, and what kind of help you will need. To learn more, visit Questions to Ask Your Doctor about Treatment.

Sources: Questions to Ask Your Doctor about Treatment

For patients · Treatment Option Overview

The following types of treatment are used:

Source: Pancreatic Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: July 8, 2026. Captured 2026-09-09.

For patients · Treatment Option Overview / The following types of treatment are used:

Surgery

Source: Pancreatic Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: July 8, 2026. Captured 2026-09-09.

One of the following types of surgery may be used to take out the tumor:

Whipple procedure is surgery to remove the head of the pancreas, the gallbladder, part of the stomach, part of the small intestine, and the bile duct. Enough of the pancreas is left to produce digestive juices and insulin.

Sources: pancreas · gallbladder · stomach · small intestine · bile duct · insulin

Total pancreatectomy is surgery to remove the whole pancreas, part of the stomach, part of the small intestine, the common bile duct, the gallbladder, the spleen, and nearby lymph nodes.

Sources: common bile duct · spleen · lymph nodes

Distal pancreatectomy is surgery to remove the body and the tail of the pancreas. The spleen may also be removed if cancer has spread to the spleen.

Sources: Distal pancreatectomy

If the cancer has spread and cannot be removed, the following types of palliative surgery may be done to relieve symptoms and improve quality of life:

Sources: palliative surgery · symptoms · quality of life

Biliary bypass: If cancer is blocking the bile duct and bile is building up in the gallbladder, a biliary bypass may be done. During this operation, the doctor will cut the gallbladder or bile duct in the area before the blockage and sew it to the small intestine to create a new pathway around the blocked area.

Sources: Biliary bypass · bile

Endoscopic stent placement: If the tumor is blocking the bile duct, surgery may be done to put in a stent (a thin tube) to drain bile that has built up in the area. The doctor may place the stent through a catheter that drains the bile into a bag on the outside of the body, or the stent may go around the blocked area and drain the bile into the small intestine.

Sources: Endoscopic · stent · catheter

Gastric bypass: If the tumor is blocking the flow of food from the stomach, the stomach may be sewn directly to the small intestine so the patient can continue to eat normally.

Sources: Gastric

For patients · Treatment Option Overview / The following types of treatment are used:

Radiation therapy

Source: Pancreatic Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: July 8, 2026. Captured 2026-09-09.

Radiation therapy uses high-energy x-rays or other types of radiation to kill cancer cells or keep them from growing. Pancreatic cancer is sometimes treated with external beam radiation therapy. This type of radiation therapy uses a machine outside the body to send radiation toward the area of the body with cancer.

Sources: Radiation therapy · x-rays · radiation · external beam radiation therapy

Learn more about External Beam Radiation Therapy for Cancer and Radiation Therapy Side Effects.

Sources: External Beam Radiation Therapy for Cancer · Radiation Therapy Side Effects

For patients · Treatment Option Overview / The following types of treatment are used:

Chemotherapy

Source: Pancreatic Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: July 8, 2026. Captured 2026-09-09.

Chemotherapy (also called chemo) uses drugs to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.

Chemotherapy for pancreatic cancer is usually systemic, meaning it is injected into a vein or given by mouth. When given this way, the drugs enter the bloodstream to reach cancer cells throughout the body.

Sources: injected

Chemotherapy drugs used to treat pancreatic cancer may include:

capecitabine

Sources: capecitabine

fluorouracil (5-FU)

Sources: fluorouracil (5-FU)

gemcitabine

Sources: gemcitabine

irinotecan

Sources: irinotecan

irinotecan sucrosofate (also called nanoliposomal irinotecan)

Sources: irinotecan sucrosofate

leucovorin (a vitamin that improves the effectiveness of 5-FU)

Sources: leucovorin

oxaliplatin

Sources: oxaliplatin

Combinations of these drugs may be used. Other chemotherapy drugs not listed here may also be used.

Chemotherapy may also be combined with other kinds of treatment. For example, it may be combined with radiation therapy or targeted therapy.

Learn more about how chemotherapy works, how it is given, common side effects, and more at Chemotherapy to Treat Cancer and Chemotherapy and You: Support for People With Cancer.

Sources: Chemotherapy to Treat Cancer · Chemotherapy and You: Support for People With Cancer

For patients · Treatment Option Overview / The following types of treatment are used:

Chemoradiation therapy

Source: Pancreatic Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: July 8, 2026. Captured 2026-09-09.

Chemoradiation therapy combines chemotherapy and radiation therapy to increase the effects of both.

For patients · Treatment Option Overview / The following types of treatment are used:

Targeted therapy

Source: Pancreatic Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: July 8, 2026. Captured 2026-09-09.

Targeted therapy uses drugs or other substances to block the action of specific enzymes, proteins, or other molecules involved in the growth and spread of cancer cells. A small number of pancreatic cancers may respond to targeted therapy. Molecular testing of the tumor is important and can help your doctor decide whether you are a candidate for targeted therapy.

Targeted therapies used to treat pancreatic cancer include:

dabrafenib with trametinib

Sources: dabrafenib · trametinib

entrectinib

Sources: entrectinib

erlotinib

Sources: erlotinib

larotrectinib

Sources: larotrectinib

olaparib

Sources: olaparib

selpercatinib

Sources: selpercatinib

zenocutuzumab-zbco

Sources: zenocutuzumab-zbco

Daraxonrasib is an experimental targeted therapy taken by mouth that targets mutations in the KRAS gene. Nine out of ten pancreatic cancers have this mutation, and it is one of the earliest gene changes found as the disease progresses. Daraxonrasib can have difficult side effects, such as rash and mouth sores. While not yet approved by the U.S. Food and Drug Administration (FDA), daraxonrasib is available under FDA’s expanded access, also called “compassionate use,” because it has been shown to extend survival and improve quality of life for people with advanced, previously treated pancreatic cancer.

Sources: expanded access

Learn more about Targeted Therapy to Treat Cancer.

Sources: Targeted Therapy to Treat Cancer

For patients · Treatment Option Overview

There are treatments for pain caused by pancreatic cancer.

Source: Pancreatic Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: July 8, 2026. Captured 2026-09-09.

Pain can occur when the tumor presses on nerves or other organs near the pancreas. When pain medicine is not enough, there are treatments that act on nerves in the abdomen to relieve the pain. The doctor may inject medicine into the area around affected nerves or may cut the nerves to block the feeling of pain. Radiation therapy with or without chemotherapy can also help relieve pain by shrinking the tumor. Learn more about Cancer Pain.

Sources: nerves · Cancer Pain

For patients · Treatment Option Overview

Patients with pancreatic cancer have special nutritional needs.

Source: Pancreatic Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: July 8, 2026. Captured 2026-09-09.

Surgery to remove the pancreas may affect its ability to make pancreatic enzymes that help to digest food. As a result, patients may have problems digesting food and absorbing nutrients into the body. To prevent malnutrition, the doctor may prescribe medicines that replace these enzymes.

Sources: pancreatic enzymes · nutrients · malnutrition

For patients · Treatment Option Overview

New types of treatment are being tested in clinical trials.

Source: Pancreatic Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: July 8, 2026. Captured 2026-09-09.

For some people, joining a clinical trial may be an option. There are different types of clinical trials for people with cancer. For example, a treatment trial tests new treatments or new ways of using current treatments. Supportive care and palliative care trials look at ways to improve quality of life, especially for those who have side effects from cancer and its treatment.

You can use the clinical trial search to find NCI-supported cancer clinical trials accepting participants. The search allows you to filter trials based on the type of cancer, your age, and where the trials are being done. Clinical trials supported by other organizations can be found on the ClinicalTrials.gov website.

Sources: clinical trial search · ClinicalTrials.gov

Learn more about clinical trials, including how to find and join one, at Clinical Trials Information for Patients and Caregivers.

Sources: Clinical Trials Information for Patients and Caregivers

For patients · Treatment Option Overview

Treatment for pancreatic cancer may cause side effects.

Source: Pancreatic Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: July 8, 2026. Captured 2026-09-09.

For information about side effects caused by treatment for cancer, visit our Side Effects page.

Sources: side effects · Side Effects

For patients · Treatment Option Overview

Follow-up care may be needed.

Source: Pancreatic Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: July 8, 2026. Captured 2026-09-09.

As you go through treatment, you will have follow-up tests or check-ups. Some tests that were done to diagnose or stage the cancer may be repeated to see how well the treatment is working. Decisions about whether to continue, change, or stop treatment may be based on the results of these tests.

Sources: diagnose · stage

Some of the tests will continue to be done from time to time after treatment has ended. The results of these tests can show if your condition has changed or if the cancer has recurred (come back).

For patients

Treatment of Resectable or Borderline Resectable Pancreatic Cancer

Source: Pancreatic Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: July 8, 2026. Captured 2026-09-09.

Treatment of resectable or borderline resectable pancreatic cancer may include:

Sources: resectable

chemotherapy with or without radiation therapy, followed by surgery

Sources: chemotherapy · radiation therapy

surgery

surgery, followed by chemotherapy

surgery, followed by chemoradiation

Sources: chemoradiation

a clinical trial of chemotherapy and/or radiation therapy before surgery

Sources: clinical trial

a clinical trial of chemoradiation, followed by surgery and then chemotherapy

a clinical trial of different ways of giving radiation therapy

Surgery to remove the tumor may include Whipple procedure, total pancreatectomy, or distal pancreatectomy.

Sources: Whipple procedure · total pancreatectomy · distal pancreatectomy

Palliative therapy can be started at any stage of disease. Visit the Palliative Therapy section for information about treatments that may improve quality of life or relieve symptoms in people with pancreatic cancer.

Sources: Palliative therapy · stage · Palliative Therapy · quality of life · symptoms

Learn more about these treatments in the Treatment Option Overview.

Sources: Treatment Option Overview

Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.

Sources: clinical trial search · General information

For patients

Treatment of Locally Advanced Pancreatic Cancer

Source: Pancreatic Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: July 8, 2026. Captured 2026-09-09.

Treatment of pancreatic cancer that is locally advanced may include:

Sources: locally advanced

chemotherapy with or without targeted therapy

Sources: chemotherapy · targeted therapy

chemotherapy and chemoradiation

Sources: chemoradiation

surgery (Whipple procedure, total pancreatectomy, or distal pancreatectomy)

Sources: Whipple procedure · total pancreatectomy · distal pancreatectomy

palliative surgery or stent placement to bypass blocked areas in ducts or the small intestine, and possibly chemotherapy and chemoradiation to shrink the tumor to allow for surgery

Sources: palliative · stent · bypass · ducts · small intestine

a clinical trial of new anticancer therapies together with chemotherapy or chemoradiation

Sources: clinical trial

a clinical trial of radiation therapy given during surgery or internal radiation therapy

Sources: radiation therapy · internal radiation

Palliative therapy can be started at any stage of disease. Visit the Palliative Therapy section for information about treatments that may improve quality of life or relieve symptoms in patients with pancreatic cancer.

Sources: Palliative therapy · stage · Palliative Therapy · quality of life · symptoms

Learn more about these treatments in the Treatment Option Overview.

Sources: Treatment Option Overview

Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.

Sources: clinical trial search · General information

For patients

Treatment of Metastatic or Recurrent Pancreatic Cancer

Source: Pancreatic Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: July 8, 2026. Captured 2026-09-09.

Treatment of pancreatic cancer that has metastasized or recurred may include:

Sources: metastasized · recurred

chemotherapy with or without targeted therapy

Sources: chemotherapy · targeted therapy

clinical trials of new anticancer agents with or without chemotherapy

Sources: clinical trials

Palliative therapy can be started at any stage of disease. Visit the Palliative Therapy section for information about treatments that may improve quality of life or relieve symptoms in patients with pancreatic cancer.

Sources: Palliative therapy · stage · Palliative Therapy · quality of life · symptoms

Learn more about these treatments in the Treatment Option Overview.

Sources: Treatment Option Overview

Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.

Sources: clinical trial search · General information

For patients

Palliative Therapy

Source: Pancreatic Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: July 8, 2026. Captured 2026-09-09.

Palliative therapy can improve the patient's quality of life by controlling the symptoms and complications of pancreatic cancer.

Sources: Palliative therapy · quality of life · symptoms

Palliative therapy for pancreatic cancer may include:

palliative surgery or stent placement to bypass blocked areas in ducts or the small intestine

Sources: stent · bypass · ducts · small intestine

palliative radiation therapy to help relieve pain by shrinking the tumor

Sources: radiation therapy

an injection of medicine to help relieve pain by blocking nerves in the abdomen

Sources: injection · nerves · abdomen

other palliative medical care alone

Learn more about these treatments in the Treatment Option Overview.

Sources: Treatment Option Overview

Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.

Sources: clinical trial search · General information

Studies

Fluorouracil, Gemcitabine, and Radiation Therapy in Treating Patients With Cancer of the Pancreas

NCT00003216 · COMPLETED · phase3

Pancreatic Cancer

ClinicalTrials.gov record

Gemcitabine With/Out Erlotinib in Unresectable Locally Advanced/Metastatic Pancreatic Cancer

NCT00026338 · COMPLETED · phase3

Pancreatic Cancer

ClinicalTrials.gov record

Two Chemotherapy Regimens Compared With Observation in Treating Patients With Completely Resected Pancreatic Cancer

NCT00058201 · COMPLETED · phase3

Pancreatic Cancer

ClinicalTrials.gov record

Gemcitabine With or Without Capecitabine and/or Radiation Therapy or Gemcitabine With or Without Erlotinib in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot Be Removed by Surgery

NCT00634725 · COMPLETED · phase3

Pancreatic Cancer

ClinicalTrials.gov record

A Phase III Second Line Trial in Advanced Pancreatic Cancer CONKO 003

NCT00786058 · APPROVED FOR MARKETING · Phase not reported

Pancreatic Cancer

ClinicalTrials.gov record

Phase III Study of ABI-007(Albumin-bound Paclitaxel) Plus Gemcitabine Versus Gemcitabine in Metastatic Adenocarcinoma of the Pancreas

NCT00844649 · COMPLETED · phase3

Metastatic Pancreatic Cancer

ClinicalTrials.gov record

Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery

NCT01013649 · COMPLETED · phase3

Pancreatic Adenocarcinoma, Pancreatic Ductal Adenocarcinoma, Pancreatic Intraductal Papillary-Mucinous Neoplasm, Stage I Pancreatic Cancer AJCC v6 and v7, Stage II Pancreatic...

ClinicalTrials.gov record

Study of MM-398 With or Without 5-FU/LV, Versus 5-FU/LV in Patients With Metastatic Pancreatic Cancer

NCT01494506 · COMPLETED · phase3

Metastatic Pancreatic Cancer

ClinicalTrials.gov record

Trial Comparing Adjuvant Chemotherapy With Gemcitabine Versus mFolfirinox to Treat Resected Pancreatic Adenocarcinoma

NCT01526135 · COMPLETED · phase3

Pancreatic Adenocarcinoma (Ductal Adenocarcinoma)

ClinicalTrials.gov record

Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy

NCT02184195 · COMPLETED · phase3

Germline BRCA1/2 Mutations and, Metastatic Adenocarcinoma of the Pancreas

ClinicalTrials.gov record

Combination Chemotherapy With or Without Hypofractionated Radiation Therapy Before Surgery in Treating Patients With Pancreatic Cancer

NCT02839343 · UNKNOWN · phase2

Pancreatic Adenocarcinoma, Borderline Resectable Adenocarcinoma of the Head of the Pancrease

ClinicalTrials.gov record

A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy)

NCT02912949 · ACTIVE NOT RECRUITING · phase2

Solid Tumours Harboring NRG1 Fusion, NSCLC Harboring NRG1 Fusion, Pancreatic Cancer Harboring NRG1 Fusion, NRG1 Fusion

ClinicalTrials.gov record

Nordic Pancreatic Cancer Trial (NorPACT) - 1

NCT02919787 · ACTIVE NOT RECRUITING · phase2, phase3

Pancreatic Cancer

ClinicalTrials.gov record

Neo-adjuvant FOLF(IRIN)OX for Resectable Pancreatic Adenocarcinoma

NCT02959879 · COMPLETED · phase2

Resectable Pancreatic Duct Adenocarcinoma

ClinicalTrials.gov record

Phase I Trial of Defactinib and VS-6766.

NCT03875820 · ACTIVE NOT RECRUITING · phase1

NSCLC, Low Grade Serous Ovarian Cancer, Endometrioid Carcinoma, Pancreatic Cancer

ClinicalTrials.gov record

Gemcitabine and Paclitaxel vs Gemcitabine Alone After FOLFIRINOX Failure in Metastatic Pancreatic Ductal Adenocarcinoma

NCT03943667 · COMPLETED · phase3

Metastatic Pancreatic Adenocarcinoma

ClinicalTrials.gov record

A Study to Assess the Effectiveness and Safety of Irinotecan Liposome Injection, 5-fluorouracil/Leucovorin Plus Oxaliplatin in Patients Not Previously Treated for Metastatic Pancreatic Cancer, Compared to Nab-paclitaxel+Gemcitabine Treatment

NCT04083235 · COMPLETED · phase3

Metastatic Adenocarcinoma of the Pancreas

ClinicalTrials.gov record

Testing the Use of the Usual Chemotherapy Before and After Surgery for Removable Pancreatic Cancer

NCT04340141 · ACTIVE NOT RECRUITING · phase3

Pancreatic Adenosquamous Carcinoma, Resectable Pancreatic Adenocarcinoma, Stage I Pancreatic Cancer AJCC v8, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8

ClinicalTrials.gov record

Perioperative or Adjuvant mFOLFIRINOX for Resectable Pancreatic Cancer

NCT04927780 · ACTIVE NOT RECRUITING · phase3

Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Adenocarcinoma

ClinicalTrials.gov record

Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)

NCT06625320 · ACTIVE NOT RECRUITING · phase3

Pancreatic Cancer, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma

ClinicalTrials.gov record

Mesothelin-Targeted Immunotoxin LMB-100 in Combination With Tofacitinib in Persons With Previously Treated Pancreatic Adenocarcinoma, Cholangiocarcinoma and Other Mesothelin Expressing Solid Tumors

NCT04034238 · COMPLETED · phase1

Neoplasms With Mesothelin Expression, Epithelioid Mesothelioma, Cholangiocarcinoma, Extrahepatic, Adenocarcinoma, Pancreatic

ClinicalTrials.gov record

Disease and treatment settings

AVGEMSI: metastatic Pancreatic Cancer (first-line)

Disease and treatment setting

1.4 Pancreatic Cancer AVGEMSI is indicated as first-line treatment for patients with locally advanced (nonresectable Stage II or Stage III) or metastatic (Stage IV) adenocarcinoma of the pancreas.

Gemcitabine: metastatic Pancreatic Cancer (first-line)

Disease and treatment setting

1.4 Pancreatic Cancer Gemcitabine Injection is indicated as first-line treatment for patients with locally advanced (nonresectable Stage II or Stage III) or metastatic (Stage IV) adenocarcinoma of the pancreas.

locally advanced Pancreatic Cancer

Disease and treatment setting

Treatment of Locally Advanced Pancreatic Cancer

metastatic Pancreatic Cancer

Disease and treatment setting

Metastatic pancreatic cancer

Pancreatic Cancer

Disease and treatment setting

Treatment of Resectable or Borderline Resectable Pancreatic Cancer

Pancreatic Cancer

Disease and treatment setting

Pancreatic Cancer

recurrent Pancreatic Cancer

Disease and treatment setting

Treatment of Metastatic or Recurrent Pancreatic Cancer

XELODA: Pancreatic Cancer (adjuvant)

Disease and treatment setting

1.4 Pancreatic Cancer XELODA is indicated for the adjuvant treatment of adults with pancreatic adenocarcinoma as a component of a combination chemotherapy regimen.